About Thyroid Eye Disease
Predicting Outcomes in Graves’ Orbitopathy
Researchers in Korea recently identified predictive factors for normalization of thyroid-stimulating immunoglobulin levels in moderate-to-severe Graves’ orbitopathy, highlighting the importance of early treatment.
In Thyroid-Associated Orbitopathy, Using Smartphones to Assess Disease Activity
A smartphone-based machine learning-assisted system for evaluating clinical activity in thyroid-associated orbitopathy may represent a promising new approach to the diagnosis and management of this condition.
Thyroid Eye Disease Differs at Presentation Among Black and White Patients
This is one of the few studies to have investigated the manifestation and treatment of thyroid eye disease in Black populations. Compared with White patients, Black patients with thyroid eye disease presented with fewer features on clinical exam. Treatments were similar in both groups, however.
Thyroid Eye Disease: The Patient’s Perspective
Even long after the active phase of thyroid eye disease has subsided, a multitude of challenging quality-of-life issues may persist.
Asymmetry in Thyroid Eye Disease: Prevalence and Characteristics
Asymmetric disease may occur in one-third of patients with thyroid eye disease, with muscle volume expansion possibly contributing to the asymmetry. A standardized definition of asymmetry using more objective parameters is needed to facilitate comparisons among studies.
Thyroid Eye Disease: Is There a Biomarker for Muscle Enlargement?
Investigators retrospectively reviewed medical records of patients with thyroid eye disease to determine the most useful biomarker for extraocular muscle enlargement.
Graves’ Orbitopathy in Thyroid Cancer: Beware Higher Doses of Radioactive Iodine
A South Korean study followed patients with thyroid cancer to assess for risk of Graves’ orbitopathy, finding an association with radioactive iodine treatment.
In Thyroid Eye Disease, Could This Be a Novel Target?
According to a study from Mayo Clinic, pregnancy-associated plasma protein A has a role in the pathogenesis of thyroid eye disease and may be a more selective target for novel therapies modulating insulin-like growth factor activity, the main driver of TED.